

**MARCH 2022** 

CARRIE HOLDEN, PHARMD



# **UTILIZATION REVIEW**


**CABENUVA** 



# CABENUVA (cabotegravir/rilpivirine)



- A long-acting complete HIV regimen given every (or every other) month
- Injectable treatment, given as 2 injections at each treatment
  - After a month of once-daily starter pills
- Flexible treatment window allowing next treatments from 7 days before to 7 days after target date
- Who might benefit?
  - Undetectable HIV in the blood
  - Challenges with or concerns about daily HIV pill routine







#### **CABENUVA DOSING**



Once-monthly dosing schedule







Cabotegravir
1 x 30-mg tablet
+
Rilpivirine
1 x 25-mg tablet

#### Oral lead-in

2 tablets once daily with a meal to assess tolerability



Every-2-month dosing schedule





# CABENUVA utilization and trends



- Utilization is trending upwards
  - **♦** *Oct 2021:* 0-9 new starts
  - ❖ *Nov & Dec 2021:* 10-19 new starts
  - ❖ Jan 2022: 20-29 new starts
- Most clients are in larger cities
  - ❖87% of all fills and 85% of unique clients have been in Los Angeles, San Diego, or San Francisco counties
- Five (5) pharmacies accounted for 88% of all new starts
- 52% of new starts have been age 25-44
  - ❖ The median ADAP client age is 55-64





# Is CABENUVA underutilized?



### References



1. cabenuva.com. 2022. *CABENUVA*. [online] Available at: <a href="https://www.cabenuva.com/">https://www.cabenuva.com/</a> [Accessed 14 March 2022].



## Confidentiality statement



By receipt of this presentation, each recipient agrees that the information contained herein will be kept confidential and that the information will not be photocopied, reproduced, or distributed to or disclosed to others at any time without the prior written consent of Magellan Health, Inc.

The information contained in this presentation is intended for educational purposes only and is not intended to define a standard of care or exclusive course of treatment, nor be a substitute for treatment.

The information contained in this presentation is intended for educational purposes only and should not be considered legal advice. Recipients are encouraged to obtain legal guidance from their own legal advisors.

